Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > ARVS > Flashcards

ARVS Flashcards

1
Q

ARV classes and key names?

A
  1. Nucleoside.nucleotide reverse transcriptase inhibitors(NRTI)-“Dine”, “Bine”, “vir”(@ the end)
  2. Non-nucleoside reverse transcriptase inhibitors (NNRT)-“vir” in the middle
  3. Protease inhibitors(PIs)-“navir”
  4. Intergrase inhibitors-“Teger”
  5. Fusion inhibitor
  6. CCR5 Antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Nucleoside nucleotide reverse transcriptase inhibitors(NRTI) drugs`/

A

D-E-A-L-S–T-Z

Didanosine

Emtricitabine (FTC)

Abacavir (ABC)

Lamivudine
(3TC)

Stavudine

  1. Tenofovir (TDF)
  2. Zidovudine (AZT, ZDV)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

NRTI MOA?

A

Resemble nucleosides/nucleotides naturally used in DNA synthesis

Compete with host nucleotides to serve as the substrate for chain elongation by reverse
transcriptase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

NRTI activation?

A

Must undergo intracellular activation to become active

Nucleoside analogs=Triphosphorylation

Nucleotide analog=Diphosphorylation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

NRTI S/E?

Specify for Tenofovir(3), Zidovudine(1), Abacavir(1) and others(4)?

A

Tenofovir:
1. Nephrotoxicty
2. Fanconi syndrome
3. Bone demineralization disorders

Zidovudine:
1. Anemia

Abacavir:
1. Fatal hypersensitivity
(HLA-B*5701 gene)

All others:
1. Peripheral neuropathy
2. Lactic acidosis
3. Pancreatitis
4. LIpodystrophy,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NNRTIs drugs?

A

“vir”

  1. Efavirenz,
  2. Nevirapine
  3. Etravirine
  4. Rilpivirine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NNRTIs MOA?

A

1.Binding site of NNRTIs is different from that of NRTIs. Inhibit HIV reverse transcriptase

  1. Do not compete with nucleoside triphosphates.
  2. Do not require intracellular activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NNRTIs A/E-3?

Specify three drugs!

A

EFV: abnormal dreams, psychosis, gynaecomastia, headache, mild to moderate
maculopapular rash

NVP: rash (may be severe or life-threatening - SJS), hepatitis

ETR: rash (may be severe or life-threatening - SJS), triglyceridaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Integrase Inhibitors drugs-3?

A

“teger”

  1. Dolutegravir
  2. Raltegravir
  3. Carbotegravir
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Integrase Inhibitors drugs MOA?

A
  1. Inhibit viral integrase enzyme
  2. Prevent the transfer of viral DNA strand into host-cell genome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Raltegravir

  1. PK
  2. DI
  3. A/E
  4. Tolerance
A

PK: bioavailability enhanced by food

DI: Rifampicin  ↓ raltegravir plasma levels

A/E: headaches, nausea, fatigue, myopathy, rhabdomyolysis

Tolerance:well-tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Integrase Inhibitors MOA-2?

A
  1. Inhibit viral integrase enzyme
  2. Prevent the transfer of viral DNA strand into host-cell genome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dolutegravir CI?

A
  • DTG may increase the risk of neural tube defects  avoid preconception
    and in the first 6 weeks of pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dolutegravir A/E?-6

A
  1. Tetratogenic
  2. insomnia
  3. weight gain
  4. headache
  5. neuropsychiatric effects
  6. diarrhea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Integrase Inhibitors DI?

A
  1. Antacids & iron supplements → ↓ Decreased DTG plasma conc. → Dose spacing
  2. Anticonvulsants (carbamazepine, phenobarbital, phenytoin) →↓ DTG
    plasma conc. →→ Avoid co-admin if possible
  3. Metformin → ↑↑↑Metforminplasma conc.→Limit metformin dose to max 500 mg 12-hourly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PIs drug-5?

A

“navir”

  1. Lopinavir
  2. Atazanavir
  3. Dorunavir
  4. Saquinavir
  5. Ritonavir
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ritonavir

A

Inhibits CYP3A4 at subtherapeutic doses

Inhibits metabolism of PIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PIs MOA?

A

Inhibits HIV protease. Prevents cleavage of viral precursor & non-infectious virions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Lopinavir/ritonavir (LPV/r) A/E-4?

A
  1. Hyperglycaemia
  2. diarrhea
  3. dyslipidemia
  4. atherosclerosis
20
Q

Atazanavir/ritonavir (ATV/r) A/E?

A
  1. Jaundice
  2. abdominal pain
21
Q

Atazanavir/ritonavir (ATV/r) usauge?

A

Used if LPV/r is not well tolerated

22
Q

Atazanavir/ritonavir (ATV/r) DI?

A

warfarin→↓ INR→↑ Coagulation

23
Q

Darunavir/ritononavir (DRV/r) DI?

A

warfarin→↓ INR→↑ Coagulation

24
Q

Darunavir/ritononavir (DRV/r) A/E?

A
  1. abdominal pain
  2. fatigue
  3. headache
25
Q

Saquinavir/ritonavir (SQV/r) A/E?

A

Prolonged QT and PR intervals

26
Q

Distinguish differences between DTG and EFV for HIV regimes

A

Check notes

27
Q

First-line regimens formula?

A

2 NRTI + NNRTI or INSTI

28
Q

Preferred first-line regimen?

A

2 NRTI + NNRTI or INSTI

Tenofovir + Lamivudine + Dolutegravir (TLD)
TDF + 3TC + DTG

29
Q

Alternative first-line regimens for patients with TB?

A

Formula: 2 NRTI + NNRTI or INSTI

TDF + FTC + EFV (TEE)

30
Q

Alternative first-line regimens for patients who are pregnant?

A

Formula: 2 NRTI + NNRTI or INSTI

TDF + FTC + EFV (TEE)

31
Q

Alternative first-line regimens for patients who are Contraindications and intolerance to EFV?

A

Normal Formula: 2 NRTI + NNRTI or INSTI

TDF + FTC + DTG (TLD

32
Q

Alternative first-line regimens for patients who are Contraindications with EFV & DTG?

A

Normal Formula: 2 NRTI + NNRTI or INSTI

TDF + 3TC/FTC + LPV/r

33
Q

Second-line Regimens ususage?

A

When Failing on first-line regimen

34
Q

Second-line Regimens formula?

A

Replace with DTG or PI

Zidovudine + (L/e) + Replacement (DTG or PI)

35
Q

Second-line Regimens on Failing on NNRTI-based (TDF+3TC/FTC+EFV/NVP) 1st line regimen?

A

AZT + 3TC + DTG

Zidovudine + Lamivudine + Dolutegravir

36
Q

Second-line Regimens if HBV positive?

A

Continue TDF because withdrawl may cause a fatal hepatitis flare

TDF + 3TC + DTG

Tenofovir+Lamivudine+ DTG

37
Q

Second-line Regimens if HBV positive Contraindication/intolerance to DTG?

A

AZT + 3TC +LPV/r

Zidovudine + Lamivudine + Lopanavir
But,

if HBsAg positive:
TDF + 3TC +LPV/r

38
Q

Second-line Regimens Contraindication/intolerance to TDF & AZT?

A

ABC + 3TC + LPV/r

Abacavir + Lamivudine + Lopinavir/Ritonavir

39
Q

Second-line Regimens failing a InSTI-based (TDF+3TC+DTG) 1st line regimen (>2 years)

A

AZT + 3TC +LPV/r
But,
if HBsAg positive:
TDF + 3TC/FTC +LPV/r

40
Q

Third-line Regimens?

A

Genotypic resistance test

resistance to LPV/r or ATV/r and/or DTG

41
Q

3RD line regime drugs available?

A
  1. PI =Darunavir (DRV)
  2. Integrase inhibitor =Raltegravir (RAL)
  3. NNRTIs= Etravirine (ETR), Rilpivirine (RPV)(MVC)
  4. CCR5 blocker = Maraviroc (MVC)
42
Q

Other drugs for 3rd regime drugs?

MOA

A/E

A

Efuvirtide(Fusion inhibitor)

MOA: Binds gp41 envelope glycoprotein thus preventing viral entry

A/E: Wheezing cough, numbness or tingling sensation

43
Q

PrEP?

A

-2 NRTI

Tenofovir + Emtriceitabine

OR

Tenofovir + Lamivudine

Hepatitis combination with tenofovir

44
Q

Post-exposure Prophylaxis (PEP)

A

TDF + 3TC + DTG

But,

If DTG contraindicated:
TDF + 3TC + ATV/r or LPV/r

If TDF contraindicated or source patient fails on TDF regimen:
AZT + 3TC + DTG
28-day Rx

45
Q

Revise the below:

  1. Combinations to avoid
  2. Mitochondrial toxicity

3.

A

CHECK NOTES

46
Q

Resistance in ART?

A
  1. K103N mutation
    * reduces NVP and EFV susceptibility by about 50 and 20-fold,
    respectively
  2. K103S mutation
    * usually occurs in samples from patients who previously had K103N
    * causes intermediate to high-level resistance to EFV and NVP
  3. K101P mutation
    * Affects all NNRTIs
    WHO, 2022
47
Q

Co-trimoxazole Preventative Therapy(CPT)?

A

Prophylaxis of PJP adn toxoplamisis in HIV patients

Pharmacology (44 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions